Collecting the impact of 20 billion markets! Stone medicine, Zhengda sunny "siege" anti-inflammatory anti-rheumatic drugs.

Pharmaceutical Network July 30, with the third batch of collection of the pace of approaching, anti-inflammatory anti-rheumatic drugs in the field of heat surge.
recently, Koren, Yangzijiang, Zhengda Qing have taken the oxytocin tofati cloth tablets; In recent years, the market size of anti-inflammatory and anti-rheumatoid drugs in Public Medical Institutions in China has been rising, exceeding 20 billion yuan in 2019.
the third batch of anti-inflammatory drugs and anti-rheumatic drugs involved in 6 generic drugs (involving 8 varieties), China Biopharmaceuticals has 3 varieties have been evaluated, Stone Pharmaceutical Group, Yangzijiang Pharmaceutical Group, Qilu Pharmaceutical s3 enterprises have 2 varieties have been evaluated.
a price fight will be played out! Stone medicine, Koren, Yangzijiang... Take the heavy varieties recently, anti-inflammatory anti-rheumatism medicine field heat is very high, oxytic acid tofatibsheet tablets, selaxeb capsules, injection with Parisib sodium and other heavy varieties have been approved for listing.
Colum Pharmaceuticals, Yangzijiang Pharmaceutical Group, Nanjing Zhengda Tianqing has taken the zicitric acid to fatati cloth tablets; Along with the approval of the products, these enterprises also further took the third batch of chips.
the first small molecule targeted JAK kinase inhibitor approved for rheumatoid arthritis in the world.
developed by Pfizer, first listed in the U.S. in 2012 and imported in China in 2017, is used to treat moderate to severe active rheumatoid arthritis that is not effective or tolerated by methotrexate.
Global sales of $2.242 billion in 2019 were $2.242 billion, up 26 percent year-on-year, according to Pfizer.
Pfizer's global sales (in millions of dollars) data show that 15 pharmaceutical companies in China have been producing acetic cloth tablets based on imitation of 4 categories of acetic acid.
2019, Zhengda Tianqing Pharmaceutical Group took the first imitation of the ziic acid tofati cloth, Qilu Pharmaceuticals 2 was approved;
seroxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2 and is mainly used to relieve the symptoms and signs of osteoarthritis, adult rheumatoid arthritis and aggressive spina bifida, as well as to treat acute pain in adults. Developed by GD Searle and Pfizer,
, the world's first selective nonsteroidal anti-inflammatory analgesic was approved for import in China in 2012.
-minnet data show that in 2019 China's public medical institutions terminal sales of more than 1 billion yuan.
at present, there are 14 pharmaceutical companies in China according to the imitation of 4 categories of reported production of silcean capsules.
November 2019, Hengrui Pharmaceuticals' Selaxib capsule was the first to be approved, and the product was subsequently approved in ZhengdaQingjiang.
in July this year, Stone Pharmaceutical Group, Baiyang Pharmaceutical's Selaxib capsules have been approved.
China's public medical institutions terminal sales of silceable capsules (units: 10,000 yuan) anti-inflammatory anti-rheumatoid medicine market exceeded 20 billion, 16 varieties have been evaluated in recent years, the domestic anti-inflammatory drugs and anti-rheumatism drugs market market continues to rise. according to
-meter net data, sales of anti-inflammatory drugs and anti-rheumatic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions) in 2019 successfully crossed the 20 billion yuan threshold, up 12.88 percent year-on-year.
China's public medical institutions terminal anti-inflammatory drugs and anti-rheumatoid drugs sales (units: 10,000 yuan) inner net consistency evaluation database shows that as of July 28, anti-inflammatory drugs and anti-rheumatism drugs have 16 varieties (54 standards) through / as if you pass the consistency evaluation, ibuprofen particles, fentanyl acid tofati cloth tablets, selache capsules and other popular varieties of the most number of enterprises.
through /like through the consistency evaluation of anti-inflammatory drugs and anti-rheumatoid drugs 8 varieties of enterprises up to 3 and above, 7 varieties of only 1 enterprise has been rated, respectively, flubiloxe injection, sulfate capsules, Losolofen sodium tablets, dichlorofenate sodium release tablets, ketosic acid abutyl injection, hydroaminotic glucose capsules, hydrochloric acid glucosathan.
16 evaluated anti-inflammatory drugs and anti-rheumatic drugs, fluorobilfen ester injection seisicanfort for the first batch of varieties, "4 plus 7" collection by Ted Pharmaceuticals winning the bid, "4 plus 7" expansion of the time Ted Pharmaceuticals and Da'an Pharmaceutical scored;
8 varieties will be collected, Zhengda, Qilu, stone medicine ... The war in the industry's attention in the third batch of 86 standards have started information collection.
According to the July 24 national collection meeting news, the third batch of collection is expected to open on August 18, the end of July issued the implementation plan and rules, the rules follow the second batch of collection rules, the use of 1.8 times the fuse mechanism and price reduction of 50%, the current procurement volume and the product's highest effective declaration price has come out.
according to the statistics of The Inner Net, the third batch of 56 generic drugs (involving 64 varieties, 86 regulations), involving anti-inflammatory drugs and anti-rheumatoid drugs have 6 generic drugs (involving 8 varieties), respectively, amino glucose oral normal release agent type, ibuprofen slow release control agent type, ibuprofen particles, selazepu oral oral release agent type, tother oral release type.
anti-inflammatory drugs and anti-rheumatoid drugs in the third batch of proposed collection of varieties competition pattern minet data show that 8 proposed collection of anti-inflammatory drugs and anti-rheumatic drugs, 5 varieties (32 standards) are still in the enterprise's imitation application in the review.
Qilu Pharmaceuticals, Collon Pharmaceuticals, Yangzijiang Pharmaceutical Group and other 9 enterprises of the Selaxib capsule listing application in the review; Haizheng Pharmaceuticals, Stone Pharmaceutical Group, Bent Pharmaceuticals and other 10 enterprises of the application for the listing of the niobium tofatib tablets in the review; Ted Pharmaceuticals, Baiyu Pharmaceuticals, Longno Pharmaceuticals relying on the application for the listing of Kaxi tablets in the review ... In addition, the state for the pharmaceutical of Selaxib capsules, Yiheng Pharmaceutical's ibuprofen slow release capsule registration status has been changed to "in approval", is expected to be approved in recent days and regarded as the same evaluation.
anti-inflammatory drugs and anti-rheumatic drugs new registration classification application in the review enterprises note that 8 proposed collection of anti-inflammatory drugs and anti-rheumatic drugs, China Biopharmaceutical has 3 varieties have been evaluated, Stone Pharmaceutical Group, Qilu Pharmaceutical, Yangzijiang Pharmaceutical Group and other 3 enterprises have 2 varieties have been evaluated.
in addition, in the review of the five varieties (32 rules), tofatitib, relying on Kaxi, Selaxicloth and other varieties, some enterprises are expected to rush to the third batch of collection before the opening of the bid approved and considered the same evaluation.
predictthat, anti-inflammatory drugs and anti-rheumatism drugs will face a fierce price war.
source: Minnet database note: statistics if there is a omission, welcome to point!